According to preliminary figures, aap Implantate AG, a medical technology company listed in the Prime Standard segment of the Frankfurt stock exchange achieved a growth in sales on product level of 10 percent to EUR 14.1 million in the first half of the 2011 fiscal year (previous year: EUR 12.8 million).The growth compared to the last six months of the previous year is mainly the result of increased sales in the fields of cement and cementing techniques as well as contract manufacturing. Compared to the last quarter of the previous year, the sales in the second quarter of 2011 rose from EUR 7.0 million to EUR 7.6 million (+ 9 percent).
Our innovative and IP-protected WSG product system was successfully launched at the end of June, with the placement of the first systems in leading German trauma hospitals. Consequently, the scheduled launch with respect to the WSG products for trauma applications was achieved; initial sales are expected over the course of the third quarter. The international roll-out is scheduled for the third quarter of 2011.
In addition, the first deliveries of our latest antibiotic-containing collagen fleece to a leading international orthopaedic company were executed in the second quarter.
We hope to power the sales development throughout the remainder of the year 2011 with the launch of the new WSG product system and the introduction of existing and new products on new/existing markets. Aside from continuing to simplify the corporation-wide structure, we strive to optimize our IT division through international networking and standardization.
aap is planning to publish the complete quarterly report Q2/2011 on August 10, 2011.